Invest Acquisition Corporation has filed a definitive information statement to extend its deadline for completing a business combination to December 2029, with a redemption deadline set for September 22, 2026.
Browsing Category
Anti-Aging Treatments
56 posts
Anbogen Therapeutics And The University Of Tokyo Enter Collaborative Research Agreement To Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
Anbogen Therapeutics and The University of Tokyo have announced a collaborative research agreement to evaluate ABT-301 across various tumor types, aiming to accelerate clinical development.
Every Enduring Field Of Medicine Is Built On Clinical Architecture.
Analysis of how clinical architecture underpins the development and sustainability of enduring medical fields, emphasizing its importance for future healthcare.
Ascentage Pharma Appoints Dr. Faiçal Miyara As Chief Business Officer And Jim Ziegler As Chief Commercial Officer
Ascentage Pharma announces the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen leadership.
The Silicon Valley Founder Meat Grinder
A recent wave of startup failures and founder exits in Silicon Valley highlights ongoing challenges for entrepreneurs and investors.
THE STORK FOUNDATION FOR INFERTILITY OPENS 2026 GRANT APPLICATIONS TO EASE FINANCIAL BURDEN OF IVF TREATMENTS
The Stork Foundation for Infertility has announced the opening of grant applications for 2026 to help reduce costs for IVF treatments.
Ascentage Pharma Chairman And CEO Dr. Dajun Yang Named To The Medicine Maker Power List 2026
Ascentage Pharma’s Chairman and CEO Dr. Dajun Yang has been recognized in The Medicine Maker Power List 2026, highlighting his influence in the pharmaceutical industry.
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy In China
Fangzhou has launched Novo Nordisk’s once-weekly basal insulin and GLP-1 combination therapy in China, marking a significant step in diabetes treatment availability.
Neuronata-R Retains Conditional Approval In South Korea
South Korea’s regulatory agency retains conditional approval for Neuronata-R, a neurological drug, amid ongoing review processes.
4DMT Announces Positive 2-Year Data From PRISM Phase 2B Clinical Trial In A Broad Wet AMD Population
4DMT announces promising two-year data from its PRISM Phase 2b trial targeting wet AMD, indicating potential for a new treatment option.
